Browse MEGF8

Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00431 CUB domain
PF12947 EGF domain
PF07645 Calcium-binding EGF domain
PF00053 Laminin EGF domain
PF01437 Plexin repeat
Function

Acts as a negative regulator of hedgehog signaling.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001558 regulation of cell growth
GO:0001667 ameboidal-type cell migration
GO:0001702 gastrulation with mouth forming second
GO:0002011 morphogenesis of an epithelial sheet
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003143 embryonic heart tube morphogenesis
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007368 determination of left/right symmetry
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007413 axonal fasciculation
GO:0007507 heart development
GO:0008037 cell recognition
GO:0008038 neuron recognition
GO:0008361 regulation of cell size
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016049 cell growth
GO:0022604 regulation of cell morphogenesis
GO:0030307 positive regulation of cell growth
GO:0030326 embryonic limb morphogenesis
GO:0030509 BMP signaling pathway
GO:0030516 regulation of axon extension
GO:0031346 positive regulation of cell projection organization
GO:0032103 positive regulation of response to external stimulus
GO:0032535 regulation of cellular component size
GO:0035050 embryonic heart tube development
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035239 tube morphogenesis
GO:0040017 positive regulation of locomotion
GO:0042074 cell migration involved in gastrulation
GO:0045666 positive regulation of neuron differentiation
GO:0045773 positive regulation of axon extension
GO:0045927 positive regulation of growth
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048568 embryonic organ development
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048841 regulation of axon extension involved in axon guidance
GO:0048842 positive regulation of axon extension involved in axon guidance
GO:0048846 axon extension involved in axon guidance
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0055113 epiboly involved in gastrulation with mouth forming second
GO:0055123 digestive system development
GO:0060173 limb development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060971 embryonic heart tube left/right pattern formation
GO:0060972 left/right pattern formation
GO:0060976 coronary vasculature development
GO:0061371 determination of heart left/right asymmetry
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0071907 determination of digestive tract left/right asymmetry
GO:0090066 regulation of anatomical structure size
GO:0090504 epiboly
GO:0097094 craniofacial suture morphogenesis
GO:0097155 fasciculation of sensory neuron axon
GO:0097485 neuron projection guidance
GO:1902284 neuron projection extension involved in neuron projection guidance
GO:1902667 regulation of axon guidance
GO:1902669 positive regulation of axon guidance
GO:1904888 cranial skeletal system development
GO:1990138 neuron projection extension
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MEGF8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MEGF8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -3.14; FDR: 0.00545 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MEGF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1640.59
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5570.734
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1230.92
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5160.181
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8380.752
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1090.974
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0170.961
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1560.92
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1990.909
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1230.929
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6050.751
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0960.21
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MEGF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.15.55.60.384
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.1023.10.223
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916018.8-18.80.28
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.53.76.80.393
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.27.710.50.63
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEGF8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEGF8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEGF8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEGF8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MEGF8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MEGF8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMEGF8
Namemultiple EGF-like-domains 8
Aliases FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MEGF8 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.